Salvatore Campanella1, Kemal Arikan2, Claudio Babiloni3,4, Michela Balconi5, Maurizio Bertollo6, Viviana Betti7, Luigi Bianchi8, Martin Brunovsky9,10, Carla Buttinelli11, Silvia Comani6, Giorgio Di Lorenzo12,13, Daniel Dumalin14, Carles Escera15, Andreas Fallgatter16,17, Derek Fisher18, Giulia Maria Giordano19, Bahar Guntekin20, Claudio Imperatori21, Ryouhei Ishii22, Hendrik Kajosch1, Michael Kiang23, Eduardo López-Caneda24, Pascal Missonnier25, Armida Mucci19, Sebastian Olbrich26, Georges Otte27, Andrea Perrottelli19, Alessandra Pizzuti7, Diego Pinal24, Dean Salisbury28, Yingying Tang29, Paolo Tisei11, Jijun Wang29, Istvan Winkler30, Jiajin Yuan31, Oliver Pogarell32. 1. Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Belgium. 2. Kemal Arıkan Psychiatry Clinic, Istanbul, Turkey. 3. Department of Physiology and Pharmacology "Erspamer", Sapienza University of Rome, Italy. 4. San Raffaele Cassino, Cassino (FR), Italy. 5. Research Unit in Affective and Social Neuroscience, Department of Psychology, Catholic University of Milan, Milan, Italy. 6. BIND-Behavioral Imaging and Neural Dynamics Center, Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy. 7. Department of Psychology, Sapienza University of Rome, Fondazione Santa Lucia, Rome, Italy. 8. Dipartimento di Ingegneria Civile e Ingegneria Informatica (DICII), University of Rome Tor Vergata, Rome, Italy. 9. National Institute of Mental Health, Klecany Czech Republic. 10. Third Medical Faculty, Charles University, Prague, Czech Republic. 11. Department of Neurosciences, Public Health and Sense Organs (NESMOS), Sapienza University of Rome, Rome, Italy. 12. Laboratory of Psychophysiology and Cognitive Neuroscience, Chair of Psychiatry, Department of Systems Medicine, School of Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy. 13. IRCCS Fondazione Santa Lucia, Rome, Italy. 14. AZ Sint-Jan Brugge-Oostende AV, Campus Henri Serruys, Lab of Neurophysiology, Department Neurology-Psychiatry, Ostend, Belgium. 15. Brainlab-Cognitive Neuroscience Research Group, Department of Clinical Psychology and Psychobiology, Institute of Neurosciences, University of Barcelona, Barcelona, Spain. 16. Department of Psychiatry, University of Tübingen, Germany; LEAD Graduate School and Training Center, Tübingen, Germany. 17. German Center for Neurodegenerative Diseases DZNE, Tübingen, Germany. 18. Department of Psychology, Mount Saint Vincent University, and Department of Psychiatry, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada. 19. Department of Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy. 20. Department of Biophysics, School of Medicine, Istanbul Medipol University, Istanbul, Turkey. 21. Cognitive and Clinical Psychology Laboratory, Department of Human Science, European University of Rome, Rome, Italy. 22. Department of Psychiatry Osaka University Graduate School of Medicine, Osaka, Japan. 23. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 24. Psychological Neuroscience Laboratory, Center for Research in Psychology, School of Psychology, University of Minho, Braga, Portugal. 25. Mental Health Network Fribourg (RFSM), Sector of Psychiatry and Psychotherapy for Adults, Marsens, Switzerland. 26. Psychotherapy and Psychosomatics, Department for Psychiatry, University Hospital Zurich, Zurich, Switzerland. 27. Group "Neurotope", Ghent, Belgium. 28. Clinical Neurophysiology Research Laboratory, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 29. Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 30. Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Budapest, Hungary. 31. Institute of Brain and Psychological Sciences, Sichuan Normal University, Chengdu, China. 32. Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
Abstract
INTRODUCTION: The global COVID-19 pandemic has affected the economy, daily life, and mental/physical health. The latter includes the use of electroencephalography (EEG) in clinical practice and research. We report a survey of the impact of COVID-19 on the use of clinical EEG in practice and research in several countries, and the recommendations of an international panel of experts for the safe application of EEG during and after this pandemic. METHODS: Fifteen clinicians from 8 different countries and 25 researchers from 13 different countries reported the impact of COVID-19 on their EEG activities, the procedures implemented in response to the COVID-19 pandemic, and precautions planned or already implemented during the reopening of EEG activities. RESULTS: Of the 15 clinical centers responding, 11 reported a total stoppage of all EEG activities, while 4 reduced the number of tests per day. In research settings, all 25 laboratories reported a complete stoppage of activity, with 7 laboratories reopening to some extent since initial closure. In both settings, recommended precautions for restarting or continuing EEG recording included strict hygienic rules, social distance, and assessment for infection symptoms among staff and patients/participants. CONCLUSIONS: The COVID-19 pandemic interfered with the use of EEG recordings in clinical practice and even more in clinical research. We suggest updated best practices to allow safe EEG recordings in both research and clinical settings. The continued use of EEG is important in those with psychiatric diseases, particularly in times of social alarm such as the COVID-19 pandemic.
INTRODUCTION: The global COVID-19 pandemic has affected the economy, daily life, and mental/physical health. The latter includes the use of electroencephalography (EEG) in clinical practice and research. We report a survey of the impact of COVID-19 on the use of clinical EEG in practice and research in several countries, and the recommendations of an international panel of experts for the safe application of EEG during and after this pandemic. METHODS: Fifteen clinicians from 8 different countries and 25 researchers from 13 different countries reported the impact of COVID-19 on their EEG activities, the procedures implemented in response to the COVID-19 pandemic, and precautions planned or already implemented during the reopening of EEG activities. RESULTS: Of the 15 clinical centers responding, 11 reported a total stoppage of all EEG activities, while 4 reduced the number of tests per day. In research settings, all 25 laboratories reported a complete stoppage of activity, with 7 laboratories reopening to some extent since initial closure. In both settings, recommended precautions for restarting or continuing EEG recording included strict hygienic rules, social distance, and assessment for infection symptoms among staff and patients/participants. CONCLUSIONS: The COVID-19 pandemic interfered with the use of EEG recordings in clinical practice and even more in clinical research. We suggest updated best practices to allow safe EEG recordings in both research and clinical settings. The continued use of EEG is important in those with psychiatric diseases, particularly in times of social alarm such as the COVID-19 pandemic.
Authors: Derek J Fisher; Erica D Rudolph; Emma M L Ells; Verner J Knott; Alain Labelle; Philip G Tibbo Journal: Psychiatry Res Neuroimaging Date: 2019-03-20 Impact factor: 2.376
Authors: Pascal Missonnier; Anne Prévot; François R Herrmann; Joseph Ventura; Anna Padée; Marco C G Merlo Journal: J Neural Transm (Vienna) Date: 2019-12-19 Impact factor: 3.575
Authors: Artur Czeszumski; Sara Eustergerling; Anne Lang; David Menrath; Michael Gerstenberger; Susanne Schuberth; Felix Schreiber; Zadkiel Zuluaga Rendon; Peter König Journal: Front Hum Neurosci Date: 2020-02-28 Impact factor: 3.169
Authors: Kiesha Prem; Yang Liu; Timothy W Russell; Adam J Kucharski; Rosalind M Eggo; Nicholas Davies; Mark Jit; Petra Klepac Journal: Lancet Public Health Date: 2020-03-25
Authors: Hans H Liu; Michael D Ezekowitz; Michele Columbo; Oneib Khan; Jack Martin; Judith Spahr; David Yaron; Lisa Cushinotto; Luciano Kapelusznik Journal: Trials Date: 2021-09-07 Impact factor: 2.279